Tag: NASDAQ:PGNX

August 6, 2019

CMS Grants Progenics New Technology Add-On Payment for Inpatient Use of AZEDRA

Progenics Pharmaceuticals (NASDAQ:PGNX) has announced that the Centers for Medicare & Medicaid Services (CMS) approved a new technology add-on payment...
June 20, 2019

Progenics Pharmaceuticals to Initiate a Basket Trial

Progenics Pharmaceuticals (NASDAQ:PGNX) has announced it has reached a decision with the US Food and Drug Administration (FDA) on plans...
June 13, 2019

Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy

Progenics Pharmaceuticals (NASDAQ:PGNX) has announced the first patient in its Phase 2 clinical trial studying I-131 1095 radiotherapy has been...
May 14, 2019

Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration

Progenics Pharmaceuticals (NASDAQ:PGNX) has announced an exclusive agreement with ROTOP Pharmaka GmbH to develop and commercialize Progenics’ 1404 prostate specific...
February 11, 2019

Progenics Acquires AZEDRA® (iobenguane I 131) Radiopharmaceutical Manufacturing Facility

Progenics Pharmaceuticals (NASDAQ:PGNX) has announced it has acquired a manufacturing facility for AZEDRA for cash consideration of US$8 million. AZEDRA...
October 15, 2018

Biotech Update: Q3 2018 in Review

With the first three quarters of 2018 over, the Investing News Network is reviewing top news in the biotech space...
October 5, 2018

Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer

Progenics Pharmaceuticals (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced...